NCT00265434

Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: University of Jena · Academic / Other
• Sex: All
• Age: 5 Years
• Healthy volunteers: Not accepted

Summary

Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of Chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections. The prospective placebo controlled cross-over study aims at the evaluation of the efficacy of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation.

Conditions

• Cystic Fibrosis
• Chronic Rhinosinusitis

Interventions

Type	Name	Description
DRUG	Pulmozyme

Timeline

• Start date: 2005-12-01
• Primary completion: 2006-05-01
• Completion: 2006-05-01
• First posted: 2005-12-14
• Last updated: 2014-12-04

Locations

1 site across 1 country: Germany